

- V. Claim 45 is drawn to a pharmaceutical composition comprising the compound of claim 37 or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, diluent or excipient.

Applicants hereby elect Group I, claim 37, drawn to the compound 5-(3-Fluorophenyl)-3-ureidothiophene-2-carboxylic acid (S)-piperidin-3-ylamide and pharmaceutically acceptable salts thereof. Furthermore, Applicants hereby reserve the right of rejoinder with respect to Groups II, III, IV, and V, should a composition of claim 1 be found allowable and the method or pharmaceutical claims of Groups II, III, IV, and V be limited in scope to the compositions deemed allowable.

A petition for a one month extension of time is being filed herewith, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 50-3231, referencing Attorney Docket No. 101367-1P US.

Respectfully submitted,

/Jacob G. Weintraub/

Name: Jacob G. Weintraub, Esq.  
Attorney or Agent under 37 CFR 1.34  
Dated: August 30, 2010  
Reg. No.: 56,469  
Phone No.: 781 839 4182  
Global Intellectual Property, Patents,  
AstraZeneca R&D Boston,  
35, Gatehouse Drive,  
Waltham, MA 02451